

ARS-1620

Catalog No: tcsc0035119

Available Sizes

Size: 5mg

Size: 25mg

Size: 50mg

Size: 100mg

Size: 200mg

Directifications

CAS No:

1698055-85-4

Formula:

 $\mathsf{C}_{21}\mathsf{H}_{17}\mathsf{CIF}_2\mathsf{N}_4\mathsf{O}_2$

Pathway:

GPCR/G Protein

Target:

Ras

Purity / Grade:

>98%

Solubility: DMSO : \geq 53 mg/mL (123.02 mM)

Observed Molecular Weight:

Copyright 2021 Taiclone Biotech Corp.



430.84


Product Description

ARS-1620 is an atropisomeric selective **KRAS^{G12C}** inhibitor with desirable pharmacokinetics.

IC50 & Target: KRAS^{G12C[1]}

In Vitro: ARS-1620 is an atropisomeric selective KRAS^{G12C} inhibitor with desirable pharmacokinetics. ARS-1620 exhibits complete growth suppression of p.G12C cell lines (IC_{50} =150 nM) with relatively benign effects on control cell lines. It is found that ARS-1620 significantly reduces expression of the gene set in p.G12C mutant cells in a time-dependent manner but not in the p.G12S mutant cells. Following a 5-day treatment period, only a minority of G12C mutant cell lines are sensitive to ARS-1620 under monolayer culture conditions, whereas in 3D-spheroid conditions, ARS-1620 elicits a robust response (p=0.0140)^[1].

In Vivo: Following a single oral dose or 5 consecutive daily doses, ARS-1620 yields average peak tumor concentrations of 1.5 μ M (50 mg/kg) and 5.5 μ M (200 mg/kg), respectively, that enables significant KRAS^{G12C} target occupancy (>=70% G12C-TE at 200 mg/kg) for >24 hr. In MIAPaCa2 xenografts (p.G12C), ARS-1620 significantly inhibits tumor growth (p



Copyright 2021 Taiclone Biotech Corp.